
adebrelimab
Start here
In the first clinical study of HRS-4642 combined with adebrelimab in previously treated patients with metastatic KRAS G12D-mutant pancreatic cancer, the chemotherapy-free regimen showed manageable safety and preliminary antitumor activity.
Excerpted from cell.com
Coverage timeline
Follow the coverage to see the different angles.
- clinicaltrials.govAdebrelimab Plus Famitinib as Adjuvant Therapy in Non-pCR NSCLC
- cell.comPickChemotherapy-free phase 1/2 trial of HRS-4642 plus adebrelimab in previously treated metastatic KRAS G12D-mutant pancreatic cancer
In the first clinical study of HRS-4642 combined with adebrelimab in previously treated patients with metastatic KRAS G12D-mutant pancreatic cancer, the chemotherapy-free regimen showed manageable safety and preliminary antitumor activity.
Heat trend for this story
Heat now 17·Peak in the comparable set 29 (Oct 22 20:00)·Change over 24h in the comparable set +67%·Participants now 4
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.